FR2773994B1 - Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central - Google Patents
Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux centralInfo
- Publication number
- FR2773994B1 FR2773994B1 FR9800728A FR9800728A FR2773994B1 FR 2773994 B1 FR2773994 B1 FR 2773994B1 FR 9800728 A FR9800728 A FR 9800728A FR 9800728 A FR9800728 A FR 9800728A FR 2773994 B1 FR2773994 B1 FR 2773994B1
- Authority
- FR
- France
- Prior art keywords
- biodavailability
- tropism
- proteases
- delivery
- products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9800728A FR2773994B1 (fr) | 1998-01-23 | 1998-01-23 | Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9800728A FR2773994B1 (fr) | 1998-01-23 | 1998-01-23 | Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2773994A1 FR2773994A1 (fr) | 1999-07-30 |
FR2773994B1 true FR2773994B1 (fr) | 2002-10-11 |
Family
ID=9522099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR9800728A Expired - Fee Related FR2773994B1 (fr) | 1998-01-23 | 1998-01-23 | Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR2773994B1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101631568B (zh) * | 2007-03-12 | 2012-08-22 | 尼克塔治疗公司 | 低聚物-蛋白酶抑制剂偶联物 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5914332A (en) | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US7202092B2 (en) | 2001-07-13 | 2007-04-10 | Roche Diagnostics Operations, Inc. | Indinavir derivatives useful in immunoassay |
US7157561B2 (en) | 2001-07-13 | 2007-01-02 | Roche Diagnostics Operations, Inc. | Methods of inhibiting transmission of a costimulatory signal of lymphocytes |
US7193065B2 (en) | 2001-07-13 | 2007-03-20 | Roche Diagnostics Operations, Inc. | Protease inhibitor conjugates and antibodies useful in immunoassay |
US20030100088A1 (en) * | 2001-07-13 | 2003-05-29 | Sigler Gerald F. | Protease inhibitor conjugates and antibodies useful in immunoassay |
US6821744B2 (en) | 2002-10-29 | 2004-11-23 | Roche Diagnostics Operations, Inc. | Method, assay, and kit for quantifying HIV protease inhibitors |
EP3696171A1 (fr) | 2006-07-07 | 2020-08-19 | Gilead Sciences, Inc. | Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques |
ES2603617T3 (es) | 2007-02-23 | 2017-02-28 | Gilead Sciences, Inc. | Moduladores de propiedades farmacocinéticas de la terapéutica |
JP5393665B2 (ja) | 2007-07-06 | 2014-01-22 | ギリアード サイエンシーズ, インコーポレイテッド | 治療剤の薬物動態特性の調整剤 |
EP2231628B1 (fr) | 2008-01-04 | 2015-10-28 | Gilead Sciences, Inc. | Inhibiteurs du cytrochrome p450 |
US9095620B2 (en) | 2008-03-12 | 2015-08-04 | Nektar Therapeutics | Reagents |
US20110195940A1 (en) | 2008-09-17 | 2011-08-11 | Nektar Therapeutics | Protease Inhibitors Having Enhanced Features |
EP2344201A1 (fr) * | 2008-09-17 | 2011-07-20 | Nektar Therapeutics | Conjugués inhibiteurs de protéase-oligomère |
US20120108501A1 (en) * | 2009-06-12 | 2012-05-03 | Nektar Therapeutics | Protease Inhibitors |
CN108586574B (zh) * | 2018-04-26 | 2019-11-12 | 国家海洋局第三海洋研究所 | 氨基葡萄糖肽类化合物及其制备方法与应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111584A0 (en) * | 1993-11-18 | 1995-01-24 | Merck & Co Inc | Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them |
EP0930886B1 (fr) * | 1996-05-09 | 2004-06-23 | INFECTIO RECHERCHE Inc. | Preparations servant a la prevention de maladies induites par des pathogenes tels que le vih ou le hsv |
-
1998
- 1998-01-23 FR FR9800728A patent/FR2773994B1/fr not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101631568B (zh) * | 2007-03-12 | 2012-08-22 | 尼克塔治疗公司 | 低聚物-蛋白酶抑制剂偶联物 |
Also Published As
Publication number | Publication date |
---|---|
FR2773994A1 (fr) | 1999-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2773994B1 (fr) | Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central | |
MA26420A1 (fr) | Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation. | |
DZ2523A1 (fr) | Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation. | |
MA26471A1 (fr) | Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
DZ2595A1 (fr) | Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs et procédépour leur préparation. | |
ATE447947T1 (de) | Pharmazeutische zubereitungen zur behandlung von insulinresitenz | |
TWI265808B (en) | Valdecoxib compositions | |
MA26456A1 (fr) | Formulations pharmaceutiques pour la distribution prolongee de medicament. | |
MA26559A1 (fr) | Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation | |
MA23899A1 (fr) | Procede pour la preparation de derives de pyrimidinedione et -trione, triazinedione et quinazolinedione, procede de preparation de compositions pharmaceutiques les contenant et leur utilisation | |
MA26472A1 (fr) | Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
EA200100524A1 (ru) | Амиды антраниловой кислоты и их применение в качестве лекарственных средств | |
CA2293470A1 (fr) | Derives de benzimidazole | |
MA26465A1 (fr) | Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA26614A1 (fr) | Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
MA26414A1 (fr) | Derives de quinoleine et de quinazoline nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant. | |
DE60126321D1 (de) | Gelsystem zur ocularen verabreichung von arzneimitteln | |
MA26433A1 (fr) | Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant | |
DE69806801D1 (de) | Galenische präparation zur prävention und behandlung von hepatokarzinomen | |
DZ2414A1 (fr) | 2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
WO2001011086A3 (fr) | Nouvelles techniques de diagnostic de l'angiogenese, compositions et techniques de criblage pour modulateurs d'angiogenese | |
DE19580261D2 (de) | Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktion | |
ATE295174T1 (de) | Arzneimittel zur behandlung von bluthochdruck | |
MA26519A1 (fr) | Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
HUP0302333A3 (en) | The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ST | Notification of lapse |